Comparison of natural NQO2 inhibitors as a new target for cancer treatment in different cell lines

Kanser için yeni bir tedavi hedefi olan NQO2’nin doğal inhibitörlerinin farklı hücre hatlarında karşılaştırılması

Abstract: Objective: Quinones are highly reactive compounds undergoing either one- or two-electron reductions. Enzymatic one-electron reduction generates unstable semiquinone radicals which readily undergo redox cycling over NQO1 and NQO2 enzymes, in the presence of molecular oxygen, leading to the production of highly reactive oxygen species (ROS). NQO1 is responsible for detoxification where NQO2 inhibitors are found to show potent anticancerogenic effects. The aim of this study is to investigate some natural inhibitors of the NQO2 enzyme and to identify their action mechanisms over this enzyme on different cancer cell lines.

Methods: First of all the NQO2 inhibitory effects of flavonoids were investigated over enzyme kinetix and Ki values were calculated. Then the cytotoxic effects of flavonoids on different cancer cell lines such as Jurkat Clone E-6, MCF7 and HepG2 cancer cell lines were investigated via MTT test and their effects on NQO2 protein expressions via western blotting.

Results: Ki values for NQO2 inhibitory effects of the studied flavonoids are respectively, Apigenin (0.25 nM) <Kaempferol (0.55 nM) <Quercetin (1.06 nM) <Luteolin (1.54 nM). The IC50 values for flavonoids in three different cell lines were as follows: for Apigenin; 140 µM, 50 µM and 50 µM, for Kaempferol; 40 µM, 100 µM and 400 µM, for Quercetin; 10 µM, 60 µM and 50 µM, and for Luteolin; 50 µM, 60 µM and 75 µM in Jurkat Clone E-6, MCF7 and HepG2 cell lines, respectively. According to the western blotting results in Jurkat cell line, Apigenin; in MCF7, Kaempferol; significantly (p<0.05) reduced the NQO2 expression whereas in HepG2 cell lines any of them did not reveal any inhibitory effects.

Conclusion: As a result, the tested flavonoids were all inhibitors of NQO2 enzyme in nM levels and in Jurkat and MCF7 cell lines the cytotoxic effects of Apigenin and Kaempferol have been associated with NQO2 inhibition.

Keywords: NQO2, flavonoids, HepG2, MCF7, Jurkat

Özet: Amaç: Kinonlar bir veya iki elektron redüksiyonuna uğrayabilen çok reaktif maddelerdir. NQO1 ve NQO2 aracılı bir elektron redüksiyonu aracılığıyla kararsız semikuinon radikalleri meydana gelir ve bunlar reoks siklusuna girerek, oksijen varlığında reaktif oksijen türevleri (ROS) oluşmasına sebep olurlar. NQO1 detoksifikasyondan sorumlu iken, NQO2 inhibitörlerinin antikanser etkisi gösterdiği bulunmuştur. Çalışmanın amacı doğal bazı bileşiklerin NQO2 inhibitörü olup olmadığını ve bu mekanизма

*Corresponding author: Mükerrem Betül Yerer: University of Erciyes, Faculty of Pharmacy, Department of Pharmacology, Kayseri, Turkey, e-mail: mbyerer@erciyes.edu.tr
Eren Demirpolat: University of Erciyes, Faculty of Pharmacy, Department of Pharmacology, Kayseri, Turkey, e-mail: erendemirpolat@yahoo.com
Ahmet Cumaoğlu: University of Erciyes, Faculty of Pharmacy, Department of Biochemistry, Kayseri, Turkey, e-mail: ahmetcumaooglu@erciyes.edu.tr
Canan Torçuk: University of Erciyes, Faculty of Pharmacy, Department of Biochemistry, Kayseri, Turkey, e-mail: canan.aslan@ucdenver.edu
Nefise Nalan İmamoğlu: University of Erciyes, Faculty of Pharmacy, Department of Basic Sciences, Kayseri, Turkey, e-mail: nimamoglu@erciyes.edu.tr
Müberra Koşar: University of Erciyes, Faculty of Pharmacy, Department of Pharmacognosy, Kayseri, Turkey, e-mail: mkosar@erciyes.edu.tr
Mükerrem Betül Yerer et al.: Comparison of natural NQO2 inhibitors in cancer cell lines

üzerinden çeşitli kanser hücrelerinde etkili olup olmadıklarının araştırılmasıdır.

Metod: Öncelikle flavonoidlerin NQO2 enzim kinetiğini üzerine etkileri araştırılmış ve Ki değerleri hesaplanmıştır. Daha sonra Jurkat Clone E-6, MCF 7 ve HepG2 kanser hücre hatlarında hücre canlılığı testi (MTT) üzerine etkileri ve western blotlama ile NQO2 proteinleri üzerine etkileri araştırılmıştır.

Bulgular: Çalışmamızda yer alan flavonoidlerin NQO2 inhibitör etkilerine ait Ki değerleri sırasıyla şu şekildedir: Apigenin (0.25 nM) < Kamferol (0.55 nM) < Kersetin (1.06 nM) < Luteolin (1.54 nM). Flavonoidlerin Jurkat Clone E-6, MCF7 ve HepG2 olmak üzere üç farklı hücre hattındaki sitotoksisiteye ait IC50 değerleri ise sırasıyla, Apigenin için 140 µM, 50 µM ve 50 µM; Kamferol için 40 µM, 100 µM ve 400 µM; Kersetin için 10 µM, 60 µM ve 50 µM; Luteolin için 50 µM, 60 µM ve 75 µM çekildi. Jurkat hücre hattı için western blota sonuçları göre Kemferol anlamlı (p<0.05) bir şekilde NQO2 ekspresyonunu azaltırken; maddelerin hiçbiri HepG2 hücre hattı için bu gözlenmemiştir.

Sonuç: Sonuç olarak test edilen tüm flavonoidlerin nM düzeyde NQO2 inhibitörü olduğu görülmüştür. Apigenin ve Kamferolun, Jurkat ile MCF7 hücre hatlarında göstermiş olduğu sitotoksk etki ise NQO2 inhibisyonu yapmalarıyla ilişkilendirilmiştir.

Anahtar Kelimeler: NQO2, flavonoidler, HepG2, MCF7, Jurkat

DOİ 10.1515/tjb-2015-0006
Received June 9, 2014; accepted January 26, 2015

Introduction

Quinones of polycyclic aromatic hydrocarbons are abundant in all burnt organic materials, including automobile exhaust, cigarette smoke and urban air pollution [1,2]. Quinones, including benzopyrene quinones and benzoquinones are highly reactive molecules and readily undergo either one- or two-electron reduction. One-electron reduction of quinones and their derivatives by enzymes, such as cytochrome P450 reductase (P450 reductase), ubiquinone oxidoeductase, etc. generate unstable semiquinones which undergo redox cycling in the presence of molecular oxygen. This leads to the formation of highly reactive oxygen species (ROS). The ROS and electrophiles (semiquinones) that are generated by one-electron reduction of quinones cause oxidative damage, such as binding to DNA, lipid peroxidation and cytotoxicity. The various toxic effects, caused by exposure to quinones, eventually lead to hepatic, cardiovascular, nervous and renal tissue degeneration, apoptotic cell death, premature aging, cellular transformation and neoplasia [1,2].

The detoxification of quinones is catalyzed by a family of flavoproteins designated as the quinone oxidoreductases (NQOs or QRs). These molecules catalyze the two-electron reduction instead of one electron and detoxification of quinones and their derivates [1].

NAD(P)H: quinone oxidoreductase 1 (NQO1) and NRH: quinone oxidoreductase 2 (NQO2) enzymes have unique ability to catalyze the two-electron reduction of quinones to hydroquinones, thereby prevents generation of toxic semiquinone radicals, reactive oxygen species and alkylaition [3–6]. Recently expression levels or single nucleotide polymorphisms in NQO1 have been shown to be associated with numerous cancers, such as breast, prostate, colorectal, esophageal, gastric, osteosarcoma, skin, acute myeloid leukemia (AML) as well as cardiovascular diseases, Parkinson’s disease and diabetes. Correlatively, expression levels or single nucleotide polymorphisms in NQO2 are shown to be associated with AML, breast, prostate and esophageal cancer as well as cardiovascular diseases, Parkinson’s disease and schizophrenia [4].

Recent studies have revealed that NQO2 differs from NQO1 in its cofactor requirement. NQO2 uses dihydronicotinamide riboside (NRH) rather than NAD(P)H as an electron donor. Another major difference between NQO2 and NQO1 is that NQO2 is resistant to typical inhibitors of NQO1 such as dicoumarol, cibacron blue and phenindone. Analysis of the crystal structure of NQO2 revealed that it contains a specific metal binding site, which is not present in NQO1. In addition to two-electron reduction of quinone compounds, NQO1 is involved in scavenging of superoxide anion radicals, maintenance of endogenous antioxidants, 20S proteasome pathway and stabilization of p53 protein. Owing to their broad substrate specificity, NQO1 and NQO2 play an important role in the detoxification of various endogenous and exogenous quinones, including estrogen quinones which are consistent with their association with many diseases [1,6].

Flavones, including quercetin and benzo(a)pyrene, are inhibitors of NQO2 [1,2]. However, structural requirements of flavones for the inhibition of NQO2 are different from those for NQO1. The most potent flavone inhibitor known for NQO2 is quercetin. Even though overlapping substrate specificities have been observed for NQO1 and NQO2, significant differences exist in relative affinities of
the various substrates. The role of NQO2 in detoxification of quinones remains unknown [2].

This project is designed to investigate the anticancerogenic efficiencies of some NQO2 inhibitors like flavonoids such as Kaempferol, Apigenin, Luteolin and Quercetin via NQO2 (NRH or QR2) receptor in chronic myeloid leukaemia and some solid carcinoma tissues including hepatocarcinoma and breast cancer cells for the first time.

**Material and Methods**

**Materials**

Recombinant human NQO2 (rhNQO2) was purchased from Sigma, dissolved in 250 mM sucrose, and stored at -80°C. Dihydronicotinamide riboside (NRH) was prepared in Dr David Ross Lab (University of Colorado, Denver, USA) from NADH using previously reported methods [7, 8]. Flavonoids were purchased from Sigma.

**Kinetic studies**

Mechanism-based inactivation of NQO2 by this flavonoid series was assayed using purified human recombinant NQO2 (rhNQO2). In these reactions (final volume of 0.5 mL), rhNQO2 (4 µg/mL) was incubated with 0-50 nM flavonoid in the absence and presence of 25-250 µM NRH in 50 mM potassium phosphate buffer (pH 7.4) containing 5 µM FAD, 125 mM NaCl, and 1 mg/mL bovine serum albumin at room temperature. After 5 min, a 50 µL aliquot was removed and diluted 50-fold in stop buffer [50 mM potassium phosphate buffer (pH 7.4) containing 250 mM sucrose, 5 µM FAD, 0.1% (v/v) Tween 20 and 0.25 mg/mL MTT]. An aliquot (960 µL) of the mixture was then transferred to a cuvette and mixed with 200 µM NRH and 10 µM menadione (final volume of 1mL) and the linear increase in absorbance was monitored spectrophotometrically at 550 nm for 2 min at room temperature. NQO2 activity was measured as NRH-dependent menadione reductase activity using MTT as the final electron acceptor [9]. Reduction of the NRH by Apigenin, Kaempferol, Quercetin and Luteolin by reduced NQO2 was assayed at 450 nm. Km and Vmax values were calculated and Ki values were determined for each flavonoid by SigmaPlot (Version 12.0, Systat Software Inc., USA).

**Cell culture**

The cell lines used in the study were purchased from American Type Culture Collection (ATCC). Acute T cell leukemia cell line Jurkat, Clone E6-1 (ATCC Cat No. TIB-152); Human hepatocellular carcinoma cell line HepG2 (ATCC Cat No. HB-8065) and Human breast adenocarcinoma cell line MCF7 (ATCC Cat. No. HTB-22) were used in the present study. Jurkat cells were maintained in RPMI 1640 Medium and HepG2 and MCF7 cells were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM). Cell cultures were supplemented with 10% fetal bovine serum (FBS), 2 mM L-Glutamine, 100 units/mL penicillin, and 100 µg/mL streptomycin and maintained under an atmosphere of 5% CO2 with 90% relative humidity at 37°C according to standard protocols. The culture media were changed every other day.

**Western blotting analysis**

The culture medium was discarded and the six-well plate was washed three times with PBS. The plate was added with the lysis buffer containing PMSF and incubated on ice for 30 min. Then, the lysates were collected and clarified by centrifugation at 12000 rpm for 10 min at 4°C and the supernatant was collected for protein analysis. The whole protein samples were boiled for 5 min in 5×loading buffer and separated using 10% SDS-PAGE. Proteins were transferred to PVDF membranes at a current of 300 mA for 90 min. The membranes were incubated in a blocking solu-
tion of 5% fat-free milk in Tris-buffered saline plus Tween 20 (TBST) for 1 h. The membrane was incubated overnight with a specific primary antibody. The membrane was then applied to a secondary antibody conjugated to HRP for 1 h. Following another triple washing, protein bands were visualized by ECL. Rabbit NQO2 (Santa cruz sc-32942) primary antibody (1:200) and rabbit β-tubulin (sc-9104) primary antibody (1:200) were used for the immunoblotting procedure. Goat antirabbit secondary antibody (Jackson Immunoresearch 111-035-144) (1:10,000).

**Statistical analysis**

The data were expressed as mean±SEM and a statistical analysis was performed by one-way ANOVA post-hoc Tukey. The results were considered statistically significant at p<0.05.

**Results**

**Kinetic studies**

The Km unit for reduction of Luteolin, Kaempferol, Quercetin and Apigenin were determined to be 2.5, 1.9, 6.0 and 1.9 nM respectively for NQO2 mediated catalysis of CB1954 (5-aziridin-1yl)-2,4-dinitrobenzamid) (Table 1, Figure 1 and Figure 2). Enzyme catalyzed reaction, the graph of velocity against substrate concentration was non-linear for all above assays. When compared among themselves the rates of the catalysis were in following order Quercetin>Luteolin>Kaempferol=Apigenin. The tested flavonoids were all competitive inhibitors of NQO2 enzyme in nM levels.

Ki values for NQO2 inhibitory effects of the studied flavonoids are respectively, Apigenin (0.25 nM)<Kaempferol (0.55 nM)<Quercetin (1.06 nM)<Luteolin (1.54 nM).

![Figure 1: Michaelis-Menten and Lineweaver Burk plots for the kinetics of NQO2 catalysis. Reduction of Luteolin and Kaempferol by NQO2 enzyme, respectively.](image-url)
Cell viability results

The cell lines used for the cell viability assays are Jurkat Clone E-6, MCF7, HepG2. As a result of MTT assay, the IC₅₀ values for flavonoids in three different cell lines were shown in Table 2.

In Jurkat Clone E-6 cell line, Quercetin (10 µM); in MCF7 cell line, Apigenin (50 µM); in HepG2 cell line, Apigenin (50 µM) and Quercetin (50 µM) had the lowest IC₅₀ levels.

Western blotting analysis

According to the western blotting results in Jurkat cell line, Apigenin (Figure 3 and 4); in MCF7, Kaempferol (Figure 5 and 6); significantly (p<0.05) reduced the NQO2 expression whereas in HepG2 cell lines any of them did not reveal any inhibitory effects (Figure 7, 8 and 9). Melatonin was loaded as a positive control. Proteins were analysed by using Image J software (Version 1.48, NIH, USA).

Discussion

It has been well documented that alkyl phenol group present in endogenous molecules, environmental toxicants, carcinogens and chemotherapeutic drugs could undergo enzymatic oxidation by peroxidases and P450 enzymes to form transient radical species which can further oxidize to quinones [10]. Quinones are known electrophilic species that covalently react with cellular macromolecules to form DNA adducts and/or protein conjugates [10–14]. The covalent binding of quinones has been shown to lead to various forms of cytotoxicity, immunotoxicity and carcinogenesis [10–14].

On the contrary, the distribution of NQO1 and NQO2 in many tumors could have a potential impact on the development and efficacy of quinone generating or containing anticancer agents. Many solid tumors including thyroid, adrenal, breast, ovarian, cornea, colon, liver and non-small cell lungs cancers express the NQO1 gene. Expression of the NQO2 gene is high in normal human liver and
skeletal muscle [1,2,15] and minimal in the kidney, heart, pancreas, brain and red blood cells [16]. There is growing interest in the possible use of flavonoids containing molecules as promising chemotherapeutic drugs [10]. Recently, numerous flavonoids have been developed as probable antitumor agents [10,17]. The ability of NQO2 to reduce flavonoids may have significant implications against the efficacy of potential flavonoid-based anticancer drugs currently under development.

These findings may also have broad implications for the efficacy of potential flavonoids-based anticancer drugs that are currently under development.

Several structurally diverse compounds have been shown to be competitive inhibitors of NQO2, including the natural products resveratrol [18,19], quercetin [9], casimiroin [20] and melatonin [21,22] and the drugs chloroquine [16,23] and imatinib [24,25]. In this study, we have demonstrated the NQO2-catalyzed reduction of the flavonoids Apigenin, Luteolin, Kaempferol and compared with the known inhibitor Quercetin and determined the Ki values for these flavonoids for the first time. According to our results all the flavonoids were competitive inhibitors of NQO2 in nM levels. The presence of additional hydroxyl groups on C3 and B3′ positions significantly decreases the ability to inhibit NQO2. The differences in the inhibition profiles of flavones are related with hydroxyl groups (Figure 10). Detailed explanation of the interaction between NQO2 and flavonoids requires examination the X-ray crystal and NMR analyses of the complex of NQO2 and flavonoids.

Table 2: The IC₅₀ values for tested flavonoids in Jurkat Clone E-6, MCF7 and HepG2 cell lines.

| Cell line/Flavonoids | Apigenin µM | Kaempferol µM | Quercetin µM | Luteolin µM |
|----------------------|-------------|---------------|-------------|-------------|
| Jurkat Clone E-6     | 140         | 40            | 10          | 50          |
| MCF7                 | 50          | 100           | 60          | 60          |
| HepG2                | 50          | 400           | 50          | 75          |

Figure 3: NQO2 expression after treatment with IC₅₀ doses of tested flavonoids in Jurkat cell line.

Figure 4: NQO2 expression after treatment with IC₅₀ doses of tested flavonoids in Jurkat cell line (Image J analysis).
Even though to date the biological role of NQO2 is poorly understood, there are studies showing evidence for its involvement in skin carcinogenesis. The most prominent example is that NQO2 knockout mice are far more prone to develop skin tumors after the topical application of carcinogens [26]. More recently, inhibition of melanoma cell growth and clonogenicity was correlated with upregulation of NQO2 and p53 [27]. In this context, the parallel inhibition of cell growth induced by melatonin, the natural ligand of NQO2, suggests that expression of NQO2 might be another factor determining the oncostatic effects of melatonin [28]. In our study, when we compare the IC$_{50}$ levels of the flavonoids in different cell lines revealed that in Jurkat Clone E-6 cell line, Quercetin (10 µM); in MCF7 cell line, Apigenin (50 µM); in HepG2 cell line, Apigenin (50 µM) and Quercetin (50 µM) had the lowest IC$_{50}$ levels but HepG2, a primary hepatoma cell line, is more resistant to flavonoids than other cell lines. Toxic substances...
are eliminated by liver which is the major organ of xenobiotic metabolism. Liver cells contain several detoxification enzymes, such as phase I and II, for proving toxicant elimination and detoxification [29]. Furthermore, when we compare the toxicity effects of flavonoids on cell lines, it reveals that Kaempferol is less toxic than other flavonoids on HepG2 and MCF7 cell lines. These results show that the competitive inhibitors of NQO2 enzyme have cytotoxic effects on different cell lines on µM levels.

Furthermore, according to our western blotting results, in Jurkat cell line, Apigenin (Figure 3); in MCF7, Kaempferol (Figure 5); significantly (p<0.05) reduced the NQO2 expression whereas in HepG2 cell lines any of them did not reveal any inhibitory effects (Figure 7 and 9) and apigenin is the most potent molecule in terms of Jurkat NQO2 protein expression and in vitro NQO2 kinetic inhibition. These results reveal that in different cell lines different flavonoids might show their cytotoxic effect via NQO2 inhibition.

In conclusion, the tested flavonoids were all inhibitors of NQO2 enzyme in nM levels and in Jurkat and MCF7

![Figure 8: NQO2 expression after treatment with IC50 doses of tested flavonoids in HepG2 cell line (Image J Analysis).](image_url)

![Figure 9: NQO2 expression after treatment with IC50 doses of Kaempferol in Jurkat, HepG2 and MCF7 cell lines.](image_url)

![Figure 10: Chemical structures of apigenin, quercetin, kaempferol and luteolin.](image_url)
cell lines the cytotoxic effects of Apigenin and Kaempferol have been associated with NQO2 inhibition.

Since there is also heterogeneity across different melanoma cell lines, more work is needed to fully characterize the factors determining dependency of NQO2 inhibition and tumor behavior and future studies are required to understand the inhibition and regulation of NQO2 expression, its structure–function relationship with the tested flavonoids and NQO2’s role in cancer treatment.

Acknowledgments: We kindly acknowledge to Prof. Dr. David Ross and his lab colleagues from University of Colorado, Denver, USA.

Conflict of Interest: This research was supported by TÜBİTAK-SBAG-1011-110S085 and Erciyes University Scientific Research Project Council 4524, TDA-2013-4524.

References

[3] Long DJ 2nd, Jaiswal AK. NRH:quinone oxidoreductase2 (NQO2). Chem Biol Interact 2000; 129(1-2):99–112.

[4] Ross D, Siegel D. NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase), functions and pharmacogenetics. Methods Enzymol 2004; 382:115–44.

[5] Leung KK, Litchfield DW, Shilton BH. Flavin adenine dinucleotide content of quinone reductase 2: analysis and optimization for structure-function studies. Anal Biochem 2012; 420(1):8–9.

[6] Kucera HR, Livingstone M, Moscoso CG, Gaikwad NW. Evidence for NQO1 and NQO2 catalyzed reduction of ortho- and para-quinone methides. Free Radic Res 2013; 47(12):1016–26.

[7] Yan C, Kepa JK, Siegel D, Stratford iJ, Ross D. Dissecting the role of multiple reductases in bioactivation and cytotoxicity of the antitumor agent 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1). Mol Pharmacol 2008; 74(6):1657–65.

[8] Friedlos F, Jarman M, Davies LC, Boland MP, Knox RJ. Identification and characterization of novel reduced pyridinium derivatives as synthetic co-factors for the enzyme DT diaphorase (NAD(P)H dehydrogenase (quinone), EC 1.6.99.2). Biochem Pharmacol 1992; 44(1):25–31.

[9] Winger JA, Hantschel O, Superti-Furga G, Kuriyan J. The crystal structure of the leukemia drug imatinib bound to human NRH:quinone oxidoreductase 2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase. Arch Biochem Biophys 1997; 347(2):221–8.

[10] Thompson DC, Thompson JA, Sugumaran M, Moldéus P. Biological and toxicological consequences of quinone methide formation. Chem Biol Interact 1993; 86(2):129–62.

[11] Gaikwad NW, Bodell WJ. Formation of DNA adducts by microsomal and peroxidase activation of p-cresol: role of quinone methide in DNA adduct formation. Chem Biol Interact 2001; 138(3):217–29.

[12] Gaikwad NW, Bodell WJ. Formation of DNA adducts in HL-60 cells treated with the toluene metabolite p-cresol: a potential biomarker for toluene exposure. Chem Biol Interact 2003; 165(2):149–58.

[13] Gaikwad NW, Bodell WJ. Peroxidase-mediated dealkylation of tamoxifen, detected by electrospray ionization-mass spectrometry, and activation to form DNA adducts. Free Radic Biol Med 2012; 52(2):340–7.

[14] Strassburg A, Strassburg CP, Manns MP, Tyukey RH. Differential gene expression of NAD(P)H:quinone oxidoreductase and NRH:quinone oxidoreductase in human hepatocellular and biliary tissue. Mol Pharmacol 2002; 61(2):320–5.

[15] Graves PR, Kwiek JJ, Fadden P, Ray R, Hardeman K, et al. Discovery of novel targets of quinoline drugs in the human purine binding proteome. Mol Pharmacol 2002; 62(6):1364–72.

[16] Zhou Q, Yu Y, Mangrum JB, Wang X. DNA alkylation with N-methylquinolinium quinone methide to N2-dG adducts resulting in extensive stops in primer extension with DNA polymerases and subsequent suppression of 6GF expression in A549 cells. Chem Res Toxicol 2011; 24(3):402–11.

[17] Buryanovsky L, Fu Y, Boyd M, Ma Y, Hsieh TC, et al. Crystal structure of quinone reductase 2 in complex with resveratrol. Biochemistry 2004; 43(36):11417–26.

[18] Wang Z, Hsieh TC, Zhang Z, Ma Y, Wu JM. Identification and purification of resveratrol targeting proteins using immobilized resveratrol affinity chromatography. Biochem Biophys Res Commun 2004; 323(3):743–9.

[19] Maiti A, Reddy PV, Sturdy M, Marler L, Pegan SD, et al. Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities. J Med Chem 2009; 52(7):1873–84.

[20] Vella F, Gerry G, Delagrange P, Boutin JA. NRH:quinone reductase 2: an enzyme of surprises and mysteries. Biochem Pharmacol 2005; 71(1-2):1–12.

[21] Maillet F, Gerry G, Vella F, Berger S, Cougè F, et al. Characterization of the melatoninergic MT3 binding site on the NRH:quinone oxidoreductase 2 enzyme. Biochimie Pharmacol 2005; 71(1-2):74–88.

[22] Vass J, Haystead TA, Rudolph J. Kinetic mechanism of quinone oxidoreductase 2 and its inhibition by the antimalarial quinolines. Biochemistry 2004; 43(15):4538–47.

[23] Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 2007; 25(9):1035–44.

[24] Winger JA, Hantschel O, Superti-Furga G, Kuriyan J. The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2). BMC Struct Biol 2009; 9:7.

[25] Iskander K, Paquet M, Brayton C, Jaiswal AK. Deficiency of NQO2 increases susceptibility to 7,12-dimethylbenz(a)anthracene and benzo(a)pyrene-induced skin carcinogenesis. Cancer Res 2004; 64(17):5925–8.

[26] Hsieh TC, Wang Z, Hamby CV, Wu JM. Inhibition of melanoma cell proliferation by resveratrol is correlated with upregulation of NQO2 expression in A549 cells. Biochem Biophys Res Commun 2005; 334(3):223–30.
[28] Fischer TW, Zmijewski MA, Zbytek B, Sweatman TW, Slominski RM, et al. Oncostatic effects of the indole melatonin and expression of its cytosolic and nuclear receptors in cultured human melanoma cell lines. Int J Oncol 2006; 29(3):665–72.

[29] Guo L, Dial S, Shi L, Branham W, Liu J, et al. Similarities and differences in the expression of drug-metabolizing enzymes between human hepatic cell lines and primary human hepatocytes. Drug Metab Dispos 2011; 39(3):528–38.